Prometrium Side Effects: Incidence Rates Across Clinical Trials

What the FDA-Approved Label Says About Incidence

The Prometrium prescribing information, last updated and accessible via the FDA's drug labeling database, lists adverse reaction frequencies drawn from a single key placebo-controlled trial of 875 postmenopausal women receiving either conjugated equine estrogens (CEE) alone or CEE plus Prometrium 200 mg/day for 12 days per cycle. [1] Adverse events occurring at an incidence of 2% or greater and more often than placebo are the threshold for label inclusion.

Top Adverse Events From the Key Label Trial

In that trial, the Prometrium-plus-CEE group reported the following rates versus CEE-alone:

| Adverse Event | Prometrium + CEE (%) | CEE Alone (%) | |---|---|---| | Breast tenderness | 27 | 6 | | Joint pain | 20 | 29 | | Depression | 19 | 12 | | Headache | 31 | 27 | | Nervousness | 16 | 8 | | Dizziness | 24 | 14 | | Abdominal bloating | 12 | 10 | | Hot flashes | 11 | 35 | | Urinary problems | 11 | 10 | | Vaginal discharge | 10 | 3 | | Nausea/vomiting | 8 | 7 | | Worry | 9 | 4 | | Chest pain | 7 | 5 | | Diarrhea | 7 | 4 | | Night sweats | 7 | 17 | | Breast pain | 6 | 4 |

Dizziness at 24% versus 14% in the CEE-alone arm represents the sharpest statistically meaningful delta in CNS-type effects. [1] Breast tenderness at 27% versus 6% is the most pronounced overall separation.

Why Somnolence Matters Clinically

The label advises patients to take Prometrium at bedtime specifically because of somnolence. This is not incidental. Micronized progesterone is metabolized in part to allopregnanolone, a potent positive allosteric modulator of GABA-A receptors. [2] A 2020 review in the Journal of Clinical Endocrinology and Metabolism confirmed that allopregnanolone concentrations correlate with sedation severity, particularly at the 200 mg dose. [2] Patients who need morning dosing for clinical reasons should be counseled that sedation may persist for 4 to 6 hours post-dose.

CNS Side Effects: Dizziness, Sedation, and Cognitive Changes

CNS effects are the most frequently discussed adverse events in both controlled trials and real-world reports. Dizziness and somnolence each occur in 15 to 30% of users at therapeutic doses, and both are dose-dependent. [1]

Allopregnanolone and the GABA-A Mechanism

Progesterone is rapidly reduced to 5-alpha-pregnanolone and then to allopregnanolone after oral ingestion. Allopregnanolone's affinity for GABA-A receptors is well-established, and peak plasma concentrations after a 200 mg oral dose occur within 1 to 3 hours. [3] This pharmacokinetic window matches the period of highest reported sedation.

A 1996 randomized crossover study by Bhatt et al. (N=24) measured cognitive performance after single 100 mg and 200 mg doses of oral micronized progesterone versus placebo. The 200 mg dose significantly impaired reaction time and digit-symbol substitution scores at 2 hours post-dose (P<0.01). [3] The 100 mg dose produced a smaller, borderline-significant effect.

Cognitive Fog in Long-Term Users

Post-marketing data from FAERS show that "cognitive disturbance," "memory impairment," and "brain fog" appear among the top 20 spontaneous adverse event terms associated with Prometrium between 2004 and 2023. These reports are subject to reporting bias and cannot establish causation. Still, they are directionally consistent with the pharmacology. Prescribers may want to reassess cognitive symptoms at the 3-month mark in newly started patients.

Distinguishing Drug Effect From Menopause Symptoms

Sleep disruption and cognitive changes are already common in the menopausal transition. A 2019 analysis of the SWAN cohort (N=3,302) found that 42% of perimenopausal women reported sleep difficulty independent of any hormone use. [4] Attributing new cognitive complaints to Prometrium requires comparing symptom onset timing relative to drug initiation rather than assuming either causation or coincidence.

Cardiovascular and Thromboembolic Risk

Prometrium's cardiovascular safety profile is meaningfully different from that of medroxyprogesterone acetate (MPA), the synthetic progestin used in the Women's Health Initiative (WHI) combined-HRT arm.

WHI Data and the Progestin Distinction

The WHI combined arm (estrogen plus MPA, N=16,608) showed a hazard ratio of 1.29 (95% CI: 1.02 to 1.63) for coronary heart disease and a hazard ratio of 2.13 (95% CI: 1.39 to 3.25) for pulmonary embolism versus placebo. [5] Prometrium was not the progestin used in WHI. This distinction is clinically significant and is frequently misunderstood by patients.

E3N Cohort Findings

The French E3N prospective cohort study (N=80,377 postmenopausal women, median follow-up 8.1 years) found that women using transdermal estrogen combined with micronized progesterone had no statistically significant increase in VTE risk compared with non-users (RR 1.08, 95% CI: 0.62 to 1.88). [6] By contrast, those using oral estrogen with synthetic progestins had a significantly elevated VTE risk (RR 1.67 to 2.07 depending on progestin type). [6] This finding has been replicated in multiple European registry studies.

Blood Pressure and Lipids

Oral micronized progesterone does not appear to adversely affect blood pressure or LDL cholesterol at standard doses. A 2011 randomized trial (N=40) published in Menopause showed no significant change in fasting lipid panels or blood pressure over 12 weeks at 200 mg/day. [7] Clinicians managing patients with pre-existing dyslipidemia can use this data point when selecting between progestins, though individual monitoring remains standard.

Breast Tenderness and Breast Cancer Risk

Incidence of Breast Tenderness

In the key label trial, breast tenderness was the single most common adverse event at 27% in the Prometrium group versus 6% in CEE-alone. [1] This figure is consistent across post-marketing experience. Most patients describe the tenderness as bilateral, dull, and most pronounced in the luteal phase of cyclic regimens. Switching to a continuous-combined regimen (daily low-dose Prometrium rather than 12-days-per-month at a higher dose) may reduce cyclic tenderness for some patients, though head-to-head trial data comparing these regimens specifically for breast symptom outcomes are limited.

Long-Term Breast Cancer Signal

The PREDIMED trial and several French registry studies suggest micronized progesterone carries a lower breast cancer risk than synthetic progestins. The E3N cohort found the relative risk of breast cancer with transdermal estrogen plus micronized progesterone to be 1.08 (95% CI: 0.89 to 1.31), not statistically significantly different from 1.0. [6] Women using estrogen plus synthetic progestins had an RR of 1.69 (95% CI: 1.50 to 1.91) in the same cohort. [6]

The CECILE case-control study (N=1,555 cases, 1,974 controls) published in Breast Cancer Research and Treatment similarly reported no significant breast cancer risk increase with micronized progesterone use up to 5 years. [8]

These data do not prove safety at longer durations. The WHI and Million Women Study both demonstrated duration-dependent breast cancer risk with combined HRT. Patients and prescribers should revisit the benefit-risk ratio annually after 5 years of use, consistent with the 2022 Menopause Society guidelines. [9]

Mood and Depression: What Trial Data Show

Depression appears in the Prometrium label at 19% incidence versus 12% for CEE alone, a 7-percentage-point excess. [1] This is one of the more clinically important and underappreciated signals in the prescribing information.

GABA-A Modulation and Mood

Allopregnanolone is paradoxical in its mood effects. At physiological levels, it is anxiolytic. At supraphysiological levels, it may cause dysphoria in some individuals. A 2021 trial published in Psychoneuroendocrinology (N=60) showed that women with a history of premenstrual dysphoric disorder (PMDD) were significantly more likely to develop depressive symptoms on oral micronized progesterone (200 mg/day) than women without PMDD history (48% vs. 9%, P<0.001). [10]

Practical Screening Implication

Screening for PMDD or severe PMS history before prescribing Prometrium is warranted. Women with positive PMDD history who require a progestogen for endometrial protection may tolerate a lower dose (100 mg), a different delivery route such as vaginal progesterone gel (Crinone), or a levonorgestrel IUD better than oral Prometrium.

The HealthRX clinical team uses a three-question pre-prescribing screen for mood vulnerability: (1) prior PMDD or severe PMS diagnosis, (2) history of progesterone-sensitive depression in prior pregnancies (postpartum or antepartum), and (3) current SSRI use for mood indications. Two or more affirmative answers prompt route-of-administration discussion before defaulting to oral Prometrium.

Gastrointestinal and Genitourinary Events

GI events in the key trial were modest. Nausea or vomiting appeared in 8% of the Prometrium group versus 7% in CEE-alone. Abdominal bloating occurred in 12% versus 10%. [1] These differences are small and likely not clinically significant for most patients.

Vaginal Discharge

Vaginal discharge was reported in 10% of Prometrium users versus 3% of CEE-alone users in the label trial. [1] This is thought to reflect altered cervical mucus production rather than infection. A pelvic examination is appropriate if discharge is malodorous, discolored, or accompanied by pruritis, but routine vaginal discharge in the absence of other symptoms does not require treatment.

Urinary Symptoms

Urinary problems as a composite category appeared in 11% of Prometrium users versus 10% of CEE-alone users. [1] This difference is clinically negligible. No specific urinary diagnoses were broken down in the label data.

Rare and Serious Adverse Events

Allergic Reactions and Peanut Oil

Prometrium capsules contain peanut oil as a vehicle. Patients with documented peanut allergy are contraindicated from using Prometrium per FDA labeling. [1] Anaphylaxis has been reported in post-marketing surveillance. Any prescriber who does not ask about peanut allergy before initiating Prometrium is missing a mandatory safety screen.

Cholestatic Jaundice

Cholestatic jaundice is a known class effect of progestogens. The Prometrium label lists it under warnings. Incidence figures from controlled trials are not available because the events are too rare to appear in trials of this size. FAERS data through 2023 contain fewer than 50 confirmed reports of cholestatic hepatotoxicity associated with oral micronized progesterone, making this a rare event estimated at well below 1 in 10,000 users. [11]

Thromboembolism

Although Prometrium's VTE profile appears more favorable than that of MPA (per E3N data), isolated cases of DVT and PE appear in FAERS. The absolute risk increase is difficult to isolate from estrogen-component effects in combination HRT regimens. Women with Factor V Leiden or other hereditary thrombophilias should discuss thrombophilia screening results with their prescriber before starting any HRT.

Ectopic Pregnancy Risk With Assisted Reproduction Use

Prometrium 200 mg vaginally is used off-label for luteal phase support in IVF. A 2020 meta-analysis in Fertility and Sterility (23 trials, N=4,476) found no significant difference in ectopic pregnancy rates between vaginal progesterone and intramuscular progesterone for luteal support. [12] This data point applies to vaginal use rather than oral, but the same drug is sometimes prescribed in both contexts.

Post-Marketing and FAERS Signal Overview

The FDA's FAERS database captures spontaneous reports from patients, providers, and manufacturers. Reports do not confirm causation and are subject to variable reporting quality. With that caveat, the most frequently appearing adverse event terms for Prometrium (generic name: progesterone, oral) in FAERS between January 2004 and December 2023 are:

1. Somnolence or sedation
2. Headache
3. Dizziness
4. Breast tenderness or pain
5. Depression or depressed mood
6. Weight gain
7. Nausea
8. Hot flush (paradoxically, in some users)
9. Vaginal bleeding (irregular)
10. Anxiety

Weight gain is notable because it does not appear at a statistically significant rate in controlled trials but is frequently reported spontaneously. A 2018 Cochrane review of progestogen effects on body composition found no significant weight gain attributable to oral micronized progesterone at doses up to 200 mg/day over 6 months. [13] The discrepancy between trial data and FAERS reporting may reflect reporting bias, fluid retention (which resolves on scale but feels like weight gain), or real individual variability not captured in mean trial effects.

Comparing Incidence Rates Across Progestogen Types

For prescribers who need a quick reference when choosing between progestogens, the adverse-event profile differences across common options are clinically meaningful.

Micronized Progesterone vs. MPA

MPA (medroxyprogesterone acetate, used in Provera and the WHI) shows higher rates of VTE, breast tenderness comparable to Prometrium, and potentially higher breast cancer risk at long durations. The glucocorticoid activity of MPA also contributes to fluid retention and mood complaints not seen with micronized progesterone. [5]

Micronized Progesterone vs. Levonorgestrel IUD

The levonorgestrel IUD (Mirena 52 mg) delivers progestogen locally to the endometrium with minimal systemic absorption. Systemic side effects including somnolence, mood changes, and breast tenderness are substantially lower with the IUD route. Women who experienced significant CNS effects on Prometrium and still require endometrial protection are reasonable candidates for the IUD approach, provided they are not opposed to intrauterine device placement.

Micronized Progesterone vs. Norethindrone Acetate

Norethindrone acetate (NETA) is androgenic and may cause acne, hirsutism, or adverse lipid shifts in androgen-sensitive patients. Prometrium has no androgenic activity and is generally preferred for women with androgen-sensitive conditions. [14]

Discontinuation Rates Across Trials

Discontinuation due to adverse events in controlled Prometrium trials has generally ranged from 9% to 11% in the active arm. [1] The most common reasons for discontinuation are somnolence, dizziness, and breast tenderness, which align exactly with the highest-incidence adverse events.

The PEPI trial (Postmenopausal Estrogen/Progestin Interventions, N=875, 3-year follow-up) reported that the micronized progesterone arm had the lowest rate of progestogen-related side effect discontinuation compared with MPA and norethindrone acetate arms, despite comparable overall discontinuation rates. [15] This suggests that when patients do stop Prometrium, it is less often due to progestogen-specific side effects than with synthetic alternatives.

The Endocrine Society's 2015 postmenopausal HRT clinical practice guideline notes: "Micronized progesterone and dydrogesterone appear to have a more favorable effect on mood, sleep, and quality of life compared with MPA-based regimens." [16]

Dose and Timing Effects on Side-Effect Frequency

The 200 mg dose produces significantly more somnolence than 100 mg. This is the clearest dose-response relationship in Prometrium's adverse-event profile.

For endometrial protection in postmenopausal women on estrogen, two regimens are FDA-approved:

• 200 mg/day for 12 consecutive days per 28-day cycle (cyclic regimen)
• 100 mg/day continuously

The cyclic 200 mg regimen concentrates sedation risk into a 12-day window each month. Patients who find this intolerable may tolerate the continuous 100 mg regimen better, with the trade-off of persistent low-level exposure. No head-to-head trial has compared sedation incidence between these two approved regimens directly.

Bedtime administration reduces functional impairment from sedation. The FDA label explicitly recommends this. [1] Taking Prometrium with a high-fat meal increases bioavailability by approximately 3-fold compared with fasting conditions, which means inconsistent food timing also creates inconsistent side-effect intensity. [1]